• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

醛酮还原酶家族 1 成员 B10（AKR1B10）在消化系统癌症中的预后价值：一项荟萃分析。

Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.

机构信息

Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi.

Department of General Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong.

出版信息

Medicine (Baltimore). 2021 Apr 9;100(14):e25454. doi: 10.1097/MD.0000000000025454.

DOI:10.1097/MD.0000000000025454
PMID:33832153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8036041/
Abstract

BACKGROUND

Numbers of studies have reported that the expression of aldo-keto reductase family 1 member B10 (AKR1B10) is abnormal in digestive system cancers, and could be used as a prognostic biomarker. However, the results are argued. Therefore, we conduct a meta-analysis to comprehensively evaluate the prognostic value of high AKR1B10 expression for overall survival (OS), disease specific survival (DSS), and disease-free survival/recurrence-free survival (DFS/PFS) in digestive system cancers.

METHODS

Hazard ratios (HRs) with its 95% confidence intervals (CIs) were calculated to assess the prognostic value of AKR1B10 by using the random effects model. The STATA version 12.0 software were used to perform all the analyses.

RESULTS

Eleven articles including 1428 patients involved in this meta-analysis. The pooled analysis suggested that high AKR1B10 expression was not associated with OS (HR: 1.18; 95% CI: 0.69-2.00) and DFS/PFS (HR: 1.08, 95% CI: 0.67-1.76) in digestive system cancers. However, Further analysis revealed that high AKR1B10 expression indicated poor OS in oral squamous cell carcinomas (OSCC) (HR: 2.92, 95% CI: 1.86-4.58) and favorable DSS in hepatocellular carcinoma (HCC) (HR: 0.71, 95% CI: 0.52-0.97).

CONCLUSIONS

The prognostic value of high AKR1B10 expression varied in different types of digestive system cancers. Further studies exploring the prognostic role of AKR1B10 in digestive system cancers are needed.

摘要

背景

多项研究报道，醛酮还原酶家族 1 成员 B10（AKR1B10）在消化系统癌症中的表达异常，并可作为预后生物标志物。然而，结果存在争议。因此，我们进行了一项荟萃分析，以综合评估 AKR1B10 高表达对消化系统癌症总生存期（OS）、疾病特异性生存期（DSS）和无病生存期/无复发生存期（DFS/PFS）的预后价值。

方法

采用随机效应模型，通过风险比（HR）及其 95%置信区间（CI）来评估 AKR1B10 的预后价值。使用 STATA 版本 12.0 软件进行所有分析。

结果

该荟萃分析纳入了 11 项研究，共涉及 1428 例患者。汇总分析表明，AKR1B10 高表达与 OS（HR：1.18；95%CI：0.69-2.00）和 DFS/PFS（HR：1.08，95%CI：0.67-1.76）无关。然而，进一步分析显示，AKR1B10 高表达与口腔鳞状细胞癌（OSCC）的 OS 不良相关（HR：2.92，95%CI：1.86-4.58），与肝癌（HCC）的 DSS 良好相关（HR：0.71，95%CI：0.52-0.97）。

结论

AKR1B10 高表达的预后价值在不同类型的消化系统癌症中有所不同。需要进一步研究探讨 AKR1B10 在消化系统癌症中的预后作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/11c04eff42b6/medi-100-e25454-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/572ab45ad13f/medi-100-e25454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/ce1a13b11505/medi-100-e25454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/1c2fd12c0069/medi-100-e25454-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/0e18af62153b/medi-100-e25454-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/220a950f25b0/medi-100-e25454-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/6eedd6470bd6/medi-100-e25454-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/11c04eff42b6/medi-100-e25454-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/572ab45ad13f/medi-100-e25454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/ce1a13b11505/medi-100-e25454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/1c2fd12c0069/medi-100-e25454-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/0e18af62153b/medi-100-e25454-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/220a950f25b0/medi-100-e25454-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/6eedd6470bd6/medi-100-e25454-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d88/8036041/11c04eff42b6/medi-100-e25454-g007.jpg

相似文献

1
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.醛酮还原酶家族 1 成员 B10（AKR1B10）在消化系统癌症中的预后价值：一项荟萃分析。
Medicine (Baltimore). 2021 Apr 9;100(14):e25454. doi: 10.1097/MD.0000000000025454.
2
AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.AKR1B10 在肝细胞癌中的表达特征及其与临床病理特征和免疫微环境的关系。
Sci Rep. 2024 May 27;14(1):12149. doi: 10.1038/s41598-024-62323-5.
3
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.AKR1B10 的过表达预示着口腔鳞状细胞癌患者的肿瘤复发和生存时间缩短。
J Oral Pathol Med. 2019 Sep;48(8):712-719. doi: 10.1111/jop.12891. Epub 2019 Jun 25.
4
Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis.AKR1B10 在肝细胞癌中的临床价值：系统评价和荟萃分析。
PLoS One. 2022 Dec 30;17(12):e0279591. doi: 10.1371/journal.pone.0279591. eCollection 2022.
5
Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.同源盒 A5 通过诱导醛酮还原酶家族 1 成员 B10 的表达来激活 p53 通路，抑制肾上腺皮质癌细胞的增殖并促进其凋亡。
Bioengineered. 2021 Dec;12(1):1964-1975. doi: 10.1080/21655979.2021.1924545.
6
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.醛酮还原酶家族1成员B10对丙型肝炎病毒相关肝细胞癌风险的影响。
J Gastroenterol Hepatol. 2016 Jul;31(7):1315-22. doi: 10.1111/jgh.13295.
7
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.醛酮还原酶1B10的高表达是肝细胞癌患者预后良好的独立预测指标。
Gut Liver. 2014 Nov;8(6):648-54. doi: 10.5009/gnl13406. Epub 2014 Oct 7.
8
Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.醛酮还原酶作为肝细胞癌的早期生物标志物：动物模型与人类 HCC 的比较。
Dig Dis Sci. 2018 Apr;63(4):934-944. doi: 10.1007/s10620-018-4943-5. Epub 2018 Jan 30.
9
Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.血清 AKR1B10 作为肝细胞癌不良生存的指标。
J Gastroenterol. 2023 Oct;58(10):1030-1042. doi: 10.1007/s00535-023-02011-9. Epub 2023 Jul 27.
10
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.AKR1B10（醛酮还原酶家族 1 B10）在多器官微流控芯片模型中促进肺癌细胞的脑转移。
Acta Biomater. 2019 Jun;91:195-208. doi: 10.1016/j.actbio.2019.04.053. Epub 2019 Apr 26.

引用本文的文献

1
AKR1B10 and digestive tumors development: a review.醛糖还原酶1B10与消化系统肿瘤的发生发展：综述
Front Immunol. 2024 Dec 16;15:1462174. doi: 10.3389/fimmu.2024.1462174. eCollection 2024.
2
Recent Insights into Nanotechnology in Colorectal Cancer.结直肠癌纳米技术的最新见解
Appl Biochem Biotechnol. 2024 Jul;196(7):4457-4471. doi: 10.1007/s12010-023-04696-3. Epub 2023 Sep 26.
3
Overexpression of AKR1B10 Predicts Poor Prognosis in Gastric Cancer Patients Undergoing Surgical Resection.AKR1B10 过表达预示接受手术切除的胃癌患者预后不良。
Curr Oncol. 2022 Dec 21;30(1):85-99. doi: 10.3390/curroncol30010007.